Opko Health Short Interest Up 6.2% in April (OPK)
Opko Health (NYSE:OPK) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 50,337,366 shares, a growth of 6.2% from the April 15th total of 47,379,151 shares, StockRatingsNetwork reports. Approximately 23.4% of the company’s stock are short sold. Based on an average daily volume of 2,431,204 shares, the short-interest ratio is currently 20.7 days.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 26,600 shares of the stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average cost of $8.26 per share, for a total transaction of $219,716.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
OPK has been the subject of a number of recent research reports. Analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Separately, analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Finally, analysts at Ned Davis Research upgraded shares of Opko Health from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Opko Health has an average rating of “Hold” and a consensus target price of $12.50.
Shares of Opko Health (NYSE:OPK) opened at 8.32 on Thursday. Opko Health has a 52-week low of $6.14 and a 52-week high of $12.95. The stock has a 50-day moving average of $8.49 and a 200-day moving average of $9.02. The company’s market cap is $3.442 billion.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.38 earnings per share for the current fiscal year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.